News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Ameriprise Financial, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) revealing a 5.8% ownership stake in Personalis, Inc. common stock as of June 30, 2026. This ownership includes shared voting power over 6,054,599 shares and shared dispositive power over 6,086,315 shares. Ameriprise …
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A for Personalis, Inc. (PSNL). The filing indicates that as of June 30, 2026, the group beneficially owned 4,000,000 shares of Personalis common stock, representing 3.82% …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations - Chris GoughPresident and Chief Executive Officer - Rod LittleChief Financial Officer - Francesca Weissman TAKEAWAYS Net Sales -- $570.1 million, representing a 1.7% …
Edgewell Personal Care presented at Canaccord Genuity's 46th Annual Growth Conference, emphasizing that its turnaround strategy is gaining momentum. The company reported a return to organic sales growth, particularly in North America, and highlighted a strategic shift towards faster-growing categories like sun and skin …
Edgewell Personal Care's Q2 earnings call highlighted key concerns from analysts despite a positive market reaction to the company's performance. Management addressed questions regarding accelerated Q4 growth, sustainability of gross margin gains, the board's stance on acquisition offers, international brand performance, and future sales …
Dimensional Fund Advisors LP increased its holdings in Personalis, Inc. (PSNL) by 8.4% in the first quarter, now owning 1.07 million shares valued at approximately $6.8 million. Despite this, insiders have sold a significant amount of stock, and the company has a consensus "Hold" …
Edgewell Personal Care achieved organic sales growth in its fiscal third quarter, surpassing expectations for adjusted EPS and adjusted EBITDA, primarily due to improved performance in North America. The company reported net sales of US$570.1 million, an increase of 1.7% year-on-year, with North American …
Personalis (PSNL) recently reported Q2 2026 results with increased sales but wider losses, leading to a reassessment of its stock by investors. Despite strong recent share price performance, the stock is currently trading slightly above analyst targets, with a narrative fair value suggesting it …
Edgewell Personal Care (EPC) recently reported Q3 2026 results with a significant drop in net income and cut its full-year GAAP EPS guidance, impacting its investment outlook. Despite modest revenue growth and continued dividend payments, the company's profitability challenges and reduced earnings expectations are …
Edgewell Personal Care reported a return to organic sales growth in Q3 fiscal year 2026, exceeding internal expectations for adjusted EPS and EBITDA, primarily driven by improved North American performance. The company maintained the midpoint of its full-year outlook and expects stronger growth in …
Tempus AI is acquiring Personalis in an all-stock deal valued at $1.5 billion, which positions Tempus AI strategically in the high-growth MRD oncology market. Despite the long-term strategic benefits, Tempus AI's stock experienced a dip following the announcement due to market concerns over valuation, …
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Edgewell Personal Care Co. (EGZ) stocks, categorized by market value. It details various ETFs, their issuers, management styles, expense ratios, assets under management (AUM), and 3-year NAV total return. The information …
Personalis, Inc. (NASDAQ:PSNL) has received an average "Hold" rating from nine analysts, with a 12-month average price target of $14.25. Recent insider selling by executives, totaling over $5.6 million in shares, has been noted. The company's latest quarterly earnings showed mixed results, with revenue …
Edgewell Personal Care recently reported third-quarter 2026 results showing modest sales growth to US$570.1 million but a sharp drop in net income to US$13.7 million, alongside a lowered full-year 2026 GAAP EPS outlook and narrower net sales growth guidance. Despite weaker GAAP profitability and …
Personalis, Inc. (PSNL) saw its stock rise by 6.1% after reporting a 30% increase in Q2 revenue to US$22.36 million year-over-year, although net losses deepened to US$31.68 million. Despite flat sales for the first half of 2026, the company reaffirmed its full-year revenue guidance …
Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing its clinical use for minimal residual disease detection in Great Britain. This regulatory approval enables pharmaceutical companies to use the platform in multi-national clinical trials, standardizing detection and potentially accelerating drug …
Edgewell Personal Care (EPC) has revised its fiscal 2026 earnings guidance downwards and reported weaker Q3 profit metrics, with net income and EPS significantly lower than last year. Despite this, the company continues its shareholder return programs, affirming a dividend and detailing share buybacks. …
Royal Bank of Canada has raised its price target for Edgewell Personal Care (NYSE:EPC) to $35 from $26, maintaining an "outperform" rating and implying a potential upside of 25.55%. This comes despite a recent 9.1% year-over-year revenue decline and a stock drop, as the …
Personalis, Inc. (PSNL) shows promising growth in the Diagnostics & Research industry, highlighted by a 30% revenue surge driven by its advanced cancer genomic tests. Despite financial challenges like negative EPS and free cash flow deficits, analyst sentiment remains cautiously optimistic, with potential upside …
UBS Group raised its price target for Edgewell Personal Care (NYSE:EPC) to $32.00 from $29.00, maintaining a "neutral" rating, indicating a potential upside of 14.56%. This adjustment follows Edgewell's Q3 earnings beat with an EPS of $0.72 against a $0.64 consensus, although revenue missed …
Analysts have raised the 12-month price target for Edgewell Personal Care Company (EPC) stock to $32.17, up from $30.5, with individual forecasts ranging from $29 to $35. This new target suggests a potential upside of approximately 10% based on the August 5 closing price. …
Edgewell Personal Care Company (NYSE: EPC) announced it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 8:00 A.M. ET. Fran Weissman, CFO, and Chris Gough, VP Investor Relations and Treasury, will represent …
Edgewell Personal Care (NYSE: EPC) announced that its CFO, Fran Weissman, and VP of Investor Relations and Treasury, Chris Gough, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 8:00 A.M. ET. A live …
UBS has increased its price target for Edgewell Personal Care (NYSE: EPC) to $32 from $29, while maintaining a "Neutral" rating on the stock. This adjustment comes amidst other analyst actions, including RBC Capital's decision to raise their price target for Edgewell to $35 …
RBC Capital has increased its price target for Edgewell Personal Care (EPC) to $35 from $26, while reiterating an Outperform rating on the stock. This adjustment follows Edgewell Personal Care's Q3 2026 earnings call and financial results, which included updated earnings guidance for the …
Edgewell Personal Care Company (NYSE:EPC) announced a quarterly dividend of $0.15 per share, payable on October 8th to shareholders of record on September 9th. This dividend represents an annualized payout of $0.60 and a yield of approximately 2.1%, which appears well-supported by the company's …
This article compiles recent news and updates for Personalis Inc (PSNL), primarily focusing on its Q2 2026 financial results, which reported a loss but topped revenue estimates, and the significant acquisition by Tempus AI for $1.5 billion. Several reports also highlight ongoing legal inquiries …
Search by ticker symbol or company name and select a result to open its chart.